Thrombotic thrombocytopenic purpura secondary prevention
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Sogand Goudarzi, MD [2]
Overview
Overview
Effective measures for the secondary prevention of TTP include: prevention any further clinically significant allergic or anaphylactic reactions and facilitated both patients’ TTP (inherited and acquired thrombotic thrombocytopenic purpura) remissions.
Secondary Prevention
Secondary Prevention
Effective measures for the secondary prevention of TTP is prevention any further clinically significant allergic or anaphylactic reactions and facilitated both patients’ TTP (inherited and acquired thrombotic thrombocytopenic purpura) remissions. Patients who had TTP should be obsereved for signs and symptoms of relapse.[1]
- Factors that may trigger TTP or relapse, including:
- Pregnancy
- Diseases such as cancer, HIV, lupus and infections.
- Medical procedures, such as surgery, blood and marrow stem cell transplant.
- Medicines, such as ticlopidine, clopidogrel, cyclosporine A, chemotherapy, and hormone therapy(estrogens).
- Quinine
References
References
- ↑ Scully, Marie; Hunt, Beverley J.; Benjamin, Sylvia; Liesner, Ri; Rose, Peter; Peyvandi, Flora; Cheung, Betty; Machin, Samuel J. (2012). “Guidelines on the diagnosis and management of thrombotic thrombocytopenic purpura and other thrombotic microangiopathies”. British Journal of Haematology. 158 (3): 323–335. doi:10.1111/j.1365-2141.2012.09167.x. ISSN 0007-1048.
Looking for the patient version?
© 2026 MyEClinic – IFTM Institut für Telematik in der Medizin GmbH